`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`
`
`
`
`MAYNE PHARMA LLC,
`
`
`Plaintiff,
`
`
`
`v.
`
`
`PERRIGO ISRAEL PHARMACEUTICALS
`LTD. and PERRIGO CO. PLC,
`
`
`Defendant.
`
`
`
`C.A. No. ________________
`
`
`
`
`COMPLAINT
`
`Plaintiff Mayne Pharma LLC (“Mayne” or “Plaintiff”), by its undersigned attorneys, brings
`
`this action against Defendants Perrigo Israel Pharmaceuticals Ltd. and Perrigo Company plc
`
`(collectively, “Perrigo” or “Defendants”), and hereby alleges as follows:
`
`NATURE OF ACTION
`
`1.
`
`This is an action for patent infringement of U.S. Patent No. 10,857,159 (the “’159
`
`patent” or “patent-in-suit”) under the patent laws of the United States, Title 35, United States Code
`
`§ 100, et seq. This action arises from Perrigo’s submission of Abbreviated New Drug Application
`
`(“ANDA”) No. 215266 to the U.S. Food and Drug Administration (“FDA”). Through its ANDA,
`
`Perrigo seeks approval to market 0.05% halobetasol propionate topical foam, a generic version of
`
`Mayne’s LEXETTE® drug product (“Perrigo ANDA product”), prior to the expiration of the
`
`patent-in-suit.
`
`2.
`
`This is also an action under 28 U.S.C. §§ 2201–02 for a declaratory judgment of
`
`patent infringement arising under the patent laws of the United States, 35 U.S.C. § 1, et seq., and
`
`in particular under 35 U.S.C. §§ 271(a), (b), and/or (c).
`
`
`
`Case 1:21-cv-00612-UNA Document 1 Filed 04/29/21 Page 2 of 11 PageID #: 2
`
`3.
`
`Mayne is a Delaware limited liability company with a place of business at 1240
`
`THE PARTIES
`
`Sugg Parkway, Greenville, North Carolina 27834.
`
`4.
`
`Upon information and belief, Perrigo Israel Pharmaceuticals Ltd. (“Perrigo Israel”)
`
`is an Israeli corporation with a place of business at 1 Rakefet St., Shoham 608500, Israel.
`
`5.
`
`Upon information and belief, Perrigo Company plc (“Perrigo Ireland”) is an Irish
`
`corporation with a place of business at The Sharp Building, Hogan Place, Dublin 2, Ireland.
`
`6.
`
`Upon information and belief, Perrigo Israel is a wholly-owned subsidiary by
`
`Perrigo Ireland.
`
`7.
`
`Upon information and belief, Perrigo prepared and submitted ANDA No. 215266
`
`and continues to collaborate in seeking FDA approval of that application.
`
`8.
`
`Upon information and belief, Perrigo intends to commercially manufacture, market,
`
`offer for sale, and sell the Perrigo ANDA product throughout the United States, including in the
`
`State of Delaware, in the event the FDA approves ANDA No. 215266.
`
`9.
`
`Upon information and belief, Perrigo Israel manufactures, sells, markets, and
`
`distributes generic pharmaceutical products throughout the United States, including in this district,
`
`in conjunction with or under the direction of Perrigo Ireland.
`
`JURISDICTION AND VENUE
`
`10.
`
`This Court has subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331, 1338,
`
`2201, 2202 because this is a patent infringement action that arises under the patent laws of the
`
`United States, 35 U.S.C. § 100 et seq. and the Declaratory Judgment Act.
`
`11.
`
`This Court has personal jurisdiction over Perrigo Israel because, inter alia, it has
`
`purposefully availed itself of the benefits and protections of Delaware’s laws such that it should
`
`reasonably anticipate being haled into court here. Upon information and belief, Perrigo Israel
`
`2
`
`

